Tangrun Pharmaceuticals

Tangrun Pharmaceuticals is a clinical-stage biotechnology company based in Shanghai, China, focused on the development of innovative small molecule therapeutics for oncology and infectious diseases. The company is primarily recognized for its research into antiviral treatments, including a lead NS3/4A protease inhibitor for Hepatitis C that has advanced into Phase 1 clinical trials. Additionally, Tangrun maintains a research program dedicated to novel platinum-based compounds aimed at treating various cell proliferative diseases and solid tumors. Led by scientific leadership including founder Suoming Zhang, the firm leverages its expertise in medicinal chemistry and drug formulation to build a specialized pipeline. Tangrun operates as a research-intensive specialty pharma, contributing to the growing landscape of innovative drug discovery within the Chinese biotechnology sector.